SCHEMBL3011896

SCHEMBL3011896

COc1ccc(OC)c(-c2csc(N3CCC(S(=O)(=O)c4ccccc4C#N)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.49
MAPT P10636 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 6/20 0.41
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
DRD2 P14416 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
KCNH2 Q12809 1/20 0.40
MEN1 O00255 4/20 0.39
AR P10275 1/20 0.39
PKM P14618 1/20 0.39
HSD17B10 Q99714 3/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007941 0.93 AR (0.45) REV1MAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL3017432 0.91 KMT2A (0.51) REV1MAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL3013860 0.87 REV1 (0.51) REV1MAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL3019749 0.87 REV1 (0.51) REV1MAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL3016406 0.87 MAPT (0.58) MAPTSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3016944 0.87 REV1 (0.54) REV1MAPTSMN1; SMN2RAB9AKMT2A
SCHEMBL3017422 0.86 MAPT (0.53) MAPTSMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL3003508 0.86 SMN1; SMN2 (0.53) MAPTSMN1; SMN2RAB9AKMT2ANPC1
SCHEMBL3002723 0.86 PKM (0.54) REV1MAPTSMN1; SMN2KMT2AALDH1A1
SCHEMBL3012945 0.86 MAPT (0.48) MAPTSMN1; SMN2RAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA REV1 4692/4885MAPT 18/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.